[Two new anticoagulants available in 2010--Dabigatran Etexilate and Rivaroxaban: expected progresses--raised...

Area of Science:

• Pharmacology
• Hematology
• Clinical Chemistry

Context:

• Traditional anticoagulants like heparins (UFH, LMWH) and vitamin K antagonists (VKA) have limitations including parenteral administration and iatrogenicity.
• Newer oral anticoagulants targeting Factor Xa (e.g., Rivaroxaban) and Factor IIa (e.g., Dabigatran Etexilate) offer improved convenience and reduced monitoring needs.
• These novel agents are increasingly used for venous thromboembolism prevention, particularly post-orthopedic surgery.

Purpose:

• To evaluate the impact of new oral anticoagulants (NOACs) on routine and specialized coagulation assays.
• To highlight the necessity of appropriate monitoring methods for NOACs.
• To compare the bleeding risk of NOACs with traditional anticoagulants.

Summary:

• Rivaroxaban and Dabigatran Etexilate, while convenient, can interfere with standard coagulation tests (PT, aPTT) and anti-Xa/anti-IIa assays.
• Monitoring of these novel anticoagulants requires assays expressed in active product units (e.g., ng/mL), distinct from UFH/LMWH units.
• The bleeding risk associated with these new agents is comparable to that of VKAs and heparins.

Impact:

• Clinicians must be aware of potential interferences of NOACs in coagulation testing.
• Development and implementation of specific monitoring assays for NOACs are crucial for safe and effective patient management.
• Understanding the monitoring requirements for novel anticoagulants is essential for optimizing therapeutic outcomes and managing bleeding events.